|Expense Ratio (net)||N/A|
|Last Cap Gain||N/A|
|Morningstar Risk Rating||N/A|
|Beta (3Y Monthly)||N/A|
|5y Average Return||N/A|
|Average for Category||N/A|
MARLBOROUGH, Mass., Feb. 15, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO) today announced that Gerrit Dispersyn, Dr. Med. Sc., currently President and COO, has been appointed by the Board of Directors as the Company's new CEO, effective March 1.
PHIO Pharmaceuticals Corp. (PHIO) reported third quarter results and filed its Form 10-Q on November 14, 2018. Patent awards, collaborations, pre-clinical advances in the immuno-oncology programs and a financing that opens a runway until 2020 rounded out other key events from June 30 to date. In conjunction with the third quarter release, the company changed its name to PHIO Pharmaceuticals and its ticker symbol to PHIO.
NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / Healthcare demand is increasing as an aging population continues to drive new healthcare market growth. The connection between healthcare goods and services is less tied to the economy compared to other sectors, and that could make healthcare stocks the place where investors will look for a hedge as the broader markets see increasing volatility. According to Bureau of Labor Statistics data*, the fastest-growing sectors include healthcare support occupations (23.2% increase from 2016-2026) and healthcare practitioners and technical occupations (15.2%), which entail home health aides, physician assistants and nurse practitioners, among other positions.
- Appoints Gerrit Dispersyn as President and Chief Operating Officer, effective Today - Geert Cauwenbergh to Remain CEO and Member of Board of Directors - Announces Planned Change in Company Name from ...
MARLBOROUGH, Mass. , Nov. 7, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...
In the suit, which was filed in federal court on Oct. 19, the biotech claims that its former chief scientific officer downloaded its proprietary scientific data before leaving the company in 2012.
On October 3rd, 2018 RXi Pharmaceuticals Corp. (RXII) announced it had closed its $15 million public underwriting. 3.725 million shares were issued at $0.70 per share and 17.702 million prefunded warrants were issued at $0.69 per share with a $0.01 exercise price. 21.427 million seven year warrants were also issued with an exercise price of $0.70.
MARLBOROUGH, Mass., Oct. 3, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today announced the closing of its previously announced underwritten public offering of 3,725,714 units at a public offering price of $0.70 per unit and 17,702,858 pre-funded units at a public offering price of $0.69 per pre-funded unit, raising gross proceeds of approximately $15 million. The Company intends to use the net proceeds of this offering towards the development of RXi's immuno-oncology program, for other research and development activities and for general working capital. Each unit sold in this offering contained one share of common stock and one warrant to purchase one share of common stock.
MARLBOROUGH, Mass., Oct. 1, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today announced the pricing of an underwritten public offering of 21,428,572 units at a price to the public of $0.70 per unit. Each unit contains one share of common stock (or common stock equivalent) and one warrant to purchase one share of common stock.
NEW YORK, NY / ACCESSWIRE / September 28, 2018 / Rxi Pharmaceuticals saw its shares soaring on Thursday as the company presented a poster entitled, "The Use of Self-delivering RNAi to Enhance NK Cell Cytotoxicity," at the 16th Annual Discovery on Target Conference. Geron shares were going in the opposite direction and crashed hard after Wall Street learned that its collaboration with Johnson & Johnson has come to an end. RXi Pharmaceuticals Corporation shares were up a little over 28% at the close on Thursday.
- RXi to present a poster today, Wednesday, September 26, 2018 - Advancements in the Company's immuno-oncology programs will be presented demonstrating the potential of sd-rxRNA in NK cells for the use ...